CPDR is a comprehensive research program to study prostate cancer and prostate disease in the triservice military health care system. Established in 1992 (Public Law 102-172), CPDR has received funding from Congress through the U.S. Army Medical Research and Materiel Command since 1992. Since its inception, the program has progressed in an outstanding manner as evidenced by:
The largest, most comprehensive prostate cancer database in the United States. Involving the Army, Air Force, and Navy at multiple military medical centers, the program is a model for interservice cooperation and research collaboration. With approximately 26,000 prostate cancer survivors enrolled to date, the CPDR database is rapidly becoming a national resource.
The only free-standing prostate cancer research center in the U.S. This 20,000 square foot state-of-the-art basic science laboratory facility is attracting the best and brightest to study the disease. Using blood and tissues collected from volunteering military beneficiaries, the CPDR laboratory has amassed a large bank of prostate cancer specimens that are serving to unravel the genetics of the disease.
A prostate cancer clinical trials center at Walter Reed National Military Medical Center (WRNMMC). Recognizing that too few men have participated in clinical trials in the past, this Center will make state-of-the-art research trials available to deserving military health beneficiaries. The Center is open to all beneficiaries worldwide.
The information provided on this web site is for informational purposes only and is not intended to replace medical advice. You should review the information carefully with your physician(s) before adopting any of this information into your current medical plan. CPDR provides clinical and research information that is complete and in accord with the standards in existence at the time of publication. However, CPDR does not warrant that the information contained herein is in every respect accurate or complete and CPDR is not responsible for any errors or omissions or for the results obtained from the use of this information. CPDR makes no representations or warranties with resect to any treatment, action, process or application of medication by any person following the information provided by CPDR. CPDR will not be liable for any damages arising from the use of this information.
The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Department or Defense.
Please consult with your doctor before adopting any of the information found on this site into your current healthcare plan.
November 2013 Guest Speaker
Presentation: "The PSA Controversy - What Patients Should Understand"
Date: 7 November 2013
Location: WRNMMC, America Building (room TBD). Also at Fort Belvoir Community Hospital via VTC
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
Read the Novemeber 2013 Newsletter
Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.
Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, Srivastava S, Nelson PS, Porter CR
The Prostate, 2013 January [Epub ahead of print].